Overview

Efficacy and Safety of Nilotinib in Patients With a Chronic Disease of the Graft Against the Host

Status:
Completed
Trial end date:
2017-07-26
Target enrollment:
Participant gender:
Summary
Open label non-randomized multicenter phase 2 trial with direct individual benefice
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital, Lille
Collaborator:
Novartis
Treatments:
Imatinib Mesylate